Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: pharmacological chaperones, enzyme replacements and co-formulations - Amicus Therapeutics

Drug Profile

Research programme: pharmacological chaperones, enzyme replacements and co-formulations - Amicus Therapeutics

Alternative Names: AT 2221; AT3375; ATB 101/Migalastat; Chaperone monotherapy - Amicus Therapeutics; Chaperone-Enzyme Replacement Therapy - Amicus Therapeutics; Chaperone-ERT combinations - Amicus Therapeutics; Duvoglustate/rhGAA; rhGAA/AT-2220; rhGAA/duvoglustat

Latest Information Update: 28 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amicus Therapeutics
  • Class Alkaloids; Alpha-glucosidases; Glycoside hydrolases; Imino pyranoses; Pharmacological chaperones; Small molecules
  • Mechanism of Action Alpha glucosidase replacements; Glucosylceramidase replacements; Iduronidase replacements; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Fabry's disease
  • No development reported Alzheimer's disease; Gaucher's disease; Glycogen storage disease type II; Mucopolysaccharidosis I; Parkinson's disease

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Glycogen-storage-disease-type-II(Combination therapy) in USA (SC)
  • 15 Jan 2018 Early research in Fabry's disease (Combination therapy) in USA (IV)
  • 08 Jan 2018 Preclinical trials in Fabry's disease (Combination therapy) in USA (IV)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top